
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group is a promising company in the biotechnology sector with a diverse pipeline of novel oncolytic immunotherapies targeting solid tumors. The company's leading product candidate, RP1, has shown potential in treating advanced melanoma, a difficult-to-treat cancer. With a strong focus on leveraging its RPx platform to activate the immune system against cancer, Replimune Group has the potential for significant growth and success in the future.
Bears say
Replimune Group is facing a negative outlook due to the disappointing results from their RP1 treatment, with an overall response rate significantly lower than other treatments in the same patient population. In addition, the FDA has raised concerns about the trial design of their ongoing Phase 3 study and the company's limited cash resources may hinder their ability to continue development. The potential need for restructuring and decreased probability of success for RP1 ultimately led to the downgrade to a Neutral rating and a decrease in the price target to $2.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares